Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT04167748
Recruiting Not applicable

Preimplantation Genetic Testing in Women of Advanced Maternal Age

NCT04167748 · tracked via the Priya Life Science USA tracker
Sponsor
Genomic Prediction Inc
Phase
Not applicable
Started
2021-03-05
Last updated
2025-08-26

Condition(s) studied

Infertility, Female

Investigational drug(s) / intervention(s)

Preimplantation genetic testing for aneuploidy (PGT-A)

Preimplantation genetic testing for aneuploidy (PGT-A): 24-chromosome screening for aneuploidy in the preimplantation embryo (blastocyst stage)

Study summary

The GETSET trial is a prospective randomized trial designed to evaluate the clinical outcomes of incorporating preimplantation genetic testing for aneuploidies (PGT-A) in elective single embryo transfer in women between 35 and 40 years of age.

Eligibility

Sex
FEMALE
Min age
35 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: * Women undergoing IVF of between 35 and 40 years of age at IVF cycle start * Utilization of Intracytoplasmic Sperm Injection ICSI * Utilization of ejaculated or testicular sperm * Utilization of autologous or donor sperm * All Controlled Ovarian Hyperstimulation (COH) protocols Exclusion criteria: * Patients with anovulatory Polycystic ovarian syndrome (PCOS) * Utilization of donor oocytes * Utilization of gestational carrier * Recurrent Pregnancy Loss (RPL) defined as ≥ 3 consecutive miscarriages * Recurrent Implantation Failure (RIF) defined as ≥ 3 more failed embryo transfers

Primary outcome measure(s)

  • Ongoing pregnancy rate — Up to 18 months
    Number of patients who experience an ongoing pregnancy rate (\>20 weeks of gestation) after their first embryo transfer

Trial sites (1)

FacilityCityRegionStatus
IVF Florida Reproductive Associates Margate Florida Recruiting

More Genomic Prediction Inc. trials in the USA

Cell Free Preimplantation Genetic Testing Starting soon
ANXA5 M2 Haplotyping in IVF Patients and Embryos Active, not recruiting
Follow-up With Preimplantation Genetic Testing Patients Recruiting
GEnetic Testing in Elective Single Embryo Transfer (GETSET): A Randomized Clinical Trial Recruiting

Other trials for the same condition

Embryo Assessment Utilizing Timelapse Imaging in Conjunction With Preimplantation Genetic Testing for Aneuploidy With Next Generation Sequencing Enrolling by invitation
Cell Free Preimplantation Genetic Testing Starting soon
GEnetic Testing in Elective Single Embryo Transfer (GETSET): A Randomized Clinical Trial Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04167748 on ClinicalTrials.gov ↗ ← All trials in the USA